sur KEYRUS PROGIWARE (EPA:KEY)
Keyrus sells its Life Sciences CRO activities to the Astek group
On June 23, 2025, the Keyrus Group announced the sale of its Life Sciences CRO activities to the Astek Group. This transaction represents consolidated revenue of €23.5 million for 2024, involving 190 full-time equivalents. Keyrus, a recognized player in the fields of Data, Artificial Intelligence, and Digital, now wishes to focus its resources on these strategic sectors.
Astek, a French company founded in 1988, is expanding its presence in life sciences, a sector already representing 11% of its 2024 turnover. The activities taken over by Astek will now be known as Alsinova.
This transaction is part of a market consolidation strategy, essential to meeting the expectations of Big Pharma. It allows Keyrus to refocus on its core business while ensuring a promising future for its teams.
R. E.
Copyright © 2025 FinanzWire, tous droits de reproduction et de représentation réservés.
Clause de non responsabilité : bien que puisées aux meilleures sources, les informations et analyses diffusées par FinanzWire sont fournies à titre indicatif et ne constituent en aucune manière une incitation à prendre position sur les marchés financiers.
Cliquez ici pour consulter le communiqué de presse ayant servi de base à la rédaction de cette brève
Voir toutes les actualités de KEYRUS PROGIWARE